Equities research analysts predict that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will announce $78.95 million in sales for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Pacira Pharmaceuticals’ earnings. The lowest sales estimate is $75.30 million and the highest is $82.32 million. Pacira Pharmaceuticals reported sales of $70.93 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.3%. The company is expected to announce its next quarterly earnings report before the market opens on Thursday, August 2nd.
According to Zacks, analysts expect that Pacira Pharmaceuticals will report full year sales of $318.56 million for the current financial year, with estimates ranging from $311.22 million to $329.62 million. For the next financial year, analysts forecast that the business will post sales of $369.17 million per share, with estimates ranging from $347.00 million to $412.19 million. Zacks’ sales averages are an average based on a survey of research firms that cover Pacira Pharmaceuticals.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, May 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $74.61 million during the quarter, compared to analyst estimates of $73.92 million. Pacira Pharmaceuticals had a negative return on equity of 5.81% and a negative net margin of 11.45%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the company earned ($0.19) EPS.
A number of equities research analysts recently issued reports on the company. Canaccord Genuity raised their price target on Pacira Pharmaceuticals from $32.00 to $34.00 and gave the stock a “hold” rating in a research note on Monday, April 9th. Zacks Investment Research lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 4th. Mizuho reissued a “hold” rating and set a $31.00 price target on shares of Pacira Pharmaceuticals in a research note on Friday, June 29th. HC Wainwright set a $48.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 3rd. Finally, Wedbush reissued an “outperform” rating and set a $80.00 price target on shares of Pacira Pharmaceuticals in a research note on Monday, April 30th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $44.94.
Shares of NASDAQ:PCRX traded up $0.20 during trading on Monday, hitting $41.00. The company had a trading volume of 810,217 shares, compared to its average volume of 922,824. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -70.69 and a beta of 1.79. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $47.55. The company has a debt-to-equity ratio of 1.00, a current ratio of 8.66 and a quick ratio of 7.83.
In other Pacira Pharmaceuticals news, CEO David M. Stack sold 25,000 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $33.79, for a total transaction of $844,750.00. Following the completion of the sale, the chief executive officer now directly owns 115,446 shares of the company’s stock, valued at approximately $3,900,920.34. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Lauren Bullaro Riker sold 801 shares of Pacira Pharmaceuticals stock in a transaction on Monday, June 4th. The shares were sold at an average price of $33.02, for a total value of $26,449.02. Following the sale, the vice president now directly owns 9,641 shares of the company’s stock, valued at $318,345.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,093 shares of company stock valued at $1,700,983. 5.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. PointState Capital LP raised its position in Pacira Pharmaceuticals by 71.1% during the 1st quarter. PointState Capital LP now owns 2,038,153 shares of the company’s stock valued at $63,488,000 after purchasing an additional 847,146 shares in the last quarter. venBio Select Advisor LLC raised its position in Pacira Pharmaceuticals by 102.1% during the 1st quarter. venBio Select Advisor LLC now owns 1,715,072 shares of the company’s stock valued at $53,424,000 after purchasing an additional 866,500 shares in the last quarter. Schroder Investment Management Group raised its position in Pacira Pharmaceuticals by 25.1% during the 1st quarter. Schroder Investment Management Group now owns 1,225,807 shares of the company’s stock valued at $38,184,000 after purchasing an additional 245,601 shares in the last quarter. Stephens Investment Management Group LLC raised its position in Pacira Pharmaceuticals by 3.5% during the 1st quarter. Stephens Investment Management Group LLC now owns 1,051,952 shares of the company’s stock valued at $32,768,000 after purchasing an additional 35,586 shares in the last quarter. Finally, Elk Creek Partners LLC raised its position in Pacira Pharmaceuticals by 51.7% during the 1st quarter. Elk Creek Partners LLC now owns 1,002,311 shares of the company’s stock valued at $31,222,000 after purchasing an additional 341,520 shares in the last quarter.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Recommended Story: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.